Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares S&P GSCI Commodity-Indexed Trust ETF vs Inovio Pharmaceuticals Inc — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $36.08 (market cap $1.02B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: iShares S&P GSCI Commodity-Indexed Trust ETF is far larger — about 9.1× Inovio Pharmaceuticals Inc's market cap, and iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares S&P GSCI Commodity-Indexed Trust ETF for 40 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| GSG | INO | |
|---|---|---|
Market Cap | $1.02B | $112.19M |
Volume | 1,256,221 | 3,201,278 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.15 | $2.65 |
52-Week Low | $22.45 | $0.66 |
Typical Hold Time | 40 Days | 43 Days |
Enterprise Value | — | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSG trades at $36.08, up 1.23% with neutral technical signals. The company reported strong 2024 results with $51.25M revenue and $69.99M net income, though cash flow turned negative at -$932.80K. Assets remain robust at $968.15M with minimal debt, while recent news highlights commodity market volatility and energy sector exposure as key drivers.
Outlook remains cautious due to commodity price sensitivity and geopolitical risks, though strong profitability and clean balance sheet provide stability. Analyst sentiment is mixed with neutral ratings prevailing, suggesting limited near-term catalysts beyond broader commodity trends.
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
